Alltrna

Pre-clinical

Cambridge, United StatesFounded 2021alltrna.com

Alltrna, a Flagship Pioneering company, is unlocking the therapeutic potential of transfer RNA (tRNA) to create a new paradigm in genetic medicine. Its platform aims to treat thousands of diseases with a single, universal tRNA medicine by correcting shared premature termination codon (PTC) mutations. The company has demonstrated preclinical proof-of-concept for its first development candidate, AP003, and is building a robust pipeline for liver and other stop codon diseases. Backed by significant venture capital, Alltrna is led by an experienced team focused on translating its novel platform into transformative therapies.

Founded

2021

Focus

RNA & Gene Therapy

AI Company Overview

Technology Platform

A proprietary platform combining machine learning and tRNA biology to engineer programmable tRNA oligonucleotides. It designs, modifies, synthesizes, and delivers chemically modified tRNAs to restore protein production disrupted by genetic mutations, starting with premature termination codon (PTC) readthrough.

Funding History

Total raised: $541M

Series B$273MFlagship PioneeringJan 15, 2024

Series B$109MFlagship PioneeringOct 15, 2023

Series A$50MFlagship PioneeringNov 15, 2021

Series A$109MFlagship PioneeringOct 15, 2021

Opportunities

The primary opportunity is to establish tRNA as a new, universal modality in genetic medicine, capable of treating the estimated 30 million patients worldwide with Stop Codon Disease.

Success with its liver programs could enable rapid expansion into other high-value tissues (e.g., CNS, muscle) and other tRNA applications beyond PTC readthrough, leveraging its scalable platform.

Risk Factors

Key risks include the unproven clinical safety and efficacy of engineered tRNA therapeutics, the challenge of achieving specific and efficient delivery to target tissues, potential immunogenicity, and the complex regulatory and commercial pathway for a 'universal' drug intended for multiple rare disease indications.

Competitive Landscape

Alltrna competes with small molecule readthrough agents (e.g., PTC Therapeutics) and disease-specific gene therapies/editing approaches. Its differentiation lies in the potential for codon-specific precision, a platform for broad applicability across diseases sharing a mutation, and the programmability of its tRNA molecules, offering a potentially best-in-class profile for nonsense mutations.